[Influence of parathormone level on the doses of human recombinant erythropoietin in haemodialysed patients].
The purpose of the study was to determine the doses of rHuEPO, which are necessary to obtain the same correction of renal anaemia in chronically haemodialysed patients with different levels of iPTH. 25 haemodialysed patients with stable values of iPTH for at least 6 months (mean age 58 +/- 15.6 years; 6 females and 19 males on haemodialysis from 1 to 126 months) were divided into 3 groups: group 1 (7 patients) with iPTH < 100 pg/ml, group 2 (12 patients) with iPTH 100-300 pg/ml and group 3 (6 patients) with iPTH > 300 pg/ml. In all groups adequacy of haemodialysis (HD) measured by Kt/V was similar. Every month the following data were determined: Ca, P, CaxP product, HCT, HGB, Fe, transferrin saturation (TSAT) and weekly dose of rHuEPO. Patients with chronic infections, neoplastic diseases or those after blood transfusions were excluded from the study. Significantly higher weekly dose of rHuEPO was needed in patients with iPTH > 300 pg/ml to obtain similar correction of renal anaemia in comparison with patients with iPTH from 100 to 300 pg/ml. There were no statistically significant differences between the groups with respect to other data except significantly higher values of Cas in the group with iPTH > 300 pg/ml.


CONCLUSIONS
Higher doses of rHuEPO to obtain the same correction of renal anaemia are necessary only in patients with iPTH > 300 pg/ml.
Zelichowski
Grzegorz
G
Klinika Nefrologii ze Stacja Dializ Centralnego Szpitala Klinicznego WAM w Warszawie.
Olszowska
Anna
A
Lubas
Arkadiusz
A
Wańkowicz
Zofia
Z
D000368:Aged; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D004305:Dose-Response Relationship, Drug; D004921:Erythropoietin / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood*; D011994:Recombinant Proteins; D006435:Renal Dialysis / Q000009:adverse effects*; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D013997:Time Factors; D016896:Treatment Outcome
D010281:Parathyroid Hormone; D011994:Recombinant Proteins; D004921:Erythropoietin